-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/osteoarthritis-pain_research-protocol.pdf
August 05, 2010 - Patients with osteoarthritis also use over-the-counter
supplements not regulated by the FDA as pharmaceuticals … Pharmacokinetics, Indications, and Dosing of drugs to be included. … Oral drugs (trade names provided only for drugs under patent)
Drug (any trade name): acetaminophen … Non-steroidal anti-inflammatory
drugs. … Non-steroidal anti-inflammatory
drugs for low-back pain.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/indirect-comparisons_research.pdf
March 01, 2013 - Trospium chloride 60
mg once daily
Placebo Esprit Pharma and
Indevus
Pharmaceuticals Inc. … (formerly Indevus
Pharmaceuticals Inc.). … Oxybutynin 2.5 mg
twice daily
Placebo Funded by Smith and
Nephew
Pharmaceuticals Ltd. … chloride Propantheline and
placebo
Pharmcia Leo
Therapeutics,
Helsingborg, Sweden
provided the
pharmaceutical … preparations used in
this study
Toglia, 201075
Study: Post-hoc Karram,
200939
VENUS
N: 739
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/TND_0024_06-09-2008.pdf
January 01, 2008 - manic or
depressive phases, rapid cycling, mixed states), do the typical and atypical
antipsychotic drugs … For adults experiencing a first episode of schizophrenia, do the atypical
antipsychotic drugs differ … comparative
evidence that differences in adherence or persistence among the atypical
antipsychotic drugs … developmental disorders or disruptive behavior disorders,
do the typical and atypical antipsychotic drugs … Behavioral and Psychological Symptoms of Dementia (BPSD),
do the typical and atypical antipsychotic drugs
-
effectivehealthcare-admin.ahrq.gov/products/atypical-antipsychotics-off-label-update/research-protocol
March 01, 2020 - These drugs have been studied for off-label use in several conditions. … 84 published studies on atypical antipsychotics and found that the most common off-label uses of the drugs … Sub-Question 2: How do atypical antipsychotic medications compare with other drugs, including first … How do they compare within the class and with other drugs used for the conditions? … across condition, and then compared within the class and with other drugs used for the conditions.
-
effectivehealthcare-admin.ahrq.gov/products/diabetes-update-2015/research
December 01, 2019 - We searched Drugs@FDA and ClinicalTrials.gov for unpublished data. … SGLT-2] inhibitors) or metformin-based combination therapy (metformin plus one of these monotherapy drugs … Gastrointestinal adverse events were higher with metformin than other drugs except GLP-1 agonists, which … SGLT-2 inhibitors increased the risk of genital mycotic infections over other drugs.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1506.pdf
June 01, 2015 - health care sector, horizon
scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs,
devices, procedures … Information is compiled for expert comment on topics at a granular
level (i.e., similar drugs in the … Results
The table below lists the single topic for which (1) preliminary phase III data for drugs (or … Frustratingly, an
unusually high percentage of investigational drugs have not met primary endpoints
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
April 01, 2013 - Topiramate and propranolol decreased use of drugs for acute migraine attacks. … among approved drugs. … Approved drugs were more effective than off-label
drugs except for the angiotensin II receptor blocker … or approved versus off-label drugs. … or approved versus off label drugs.
-
effectivehealthcare-admin.ahrq.gov/products/allergy-seasonal/research
December 01, 2019 - We sought to compare the following classes of drugs: oral and nasal antihistamines and decongestants; … Inclusion was limited to studies that reported an outcome of interest and directly compared drugs of … Across all comparisons, 20 of 39 drugs FDA approved for the treatment of SAR were studied. … Conclusions were limited by (1) lack of comparative evidence for all drugs within each class and (2)
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/ced%20-appendix-2.xlsx
October 12, 2022 - Drugs and devices that are subject to CED should qualify for Medicare transitional pass-through status … Application of CED to on-label uses of drugs and biologicals restricts patient access. … Caution against the broad use of CED for on-label uses of drugs and biologics that have gone through … Ban CED for drugs with accelerated approval. … Recommends that on-label uses of drugs and biologicals be excluded from CED restrictions.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/dietary-supplements_research-protocol.pdf
December 15, 2010 - specific dietary
supplements (when compared to cardiovascular drugs alone or cardiovascular drugs and … Classes of commonly used cardiovascular drugs to be considered (excluding drugs used
exclusively for … Analytic Framework for Dietary Supplement Use in Adults
Taking Cardiovascular Drugs. … Drugs Aging 2009;26(Suppl 1):41-51.
4. Garner JB. … Drugs 2009;69:1777-98.
7. Miller KL, Liebowitz RS, Newby LK.
-
effectivehealthcare-admin.ahrq.gov/products/migraine-prevention/research
December 01, 2019 - percent, reduction in migraine-related disability, and improvement in quality of life with off-label drugs … (No preventive drugs were approved in children.) … Also eligible were studies that compared drugs with nonpharmacologic interventions or drug management … Long-term preventive benefits are unknown both for drugs and nonpharmacologic interventions. … Future randomized trials of drugs with favorable benefits-to-harms ratio in adults are needed to identify
-
effectivehealthcare-admin.ahrq.gov/products/dietary-supplements
March 01, 2021 - SHARE:
Dietary Supplements in Adults Taking Cardiovascular Drugs … Internet Citation:
Dietary Supplements in Adults Taking Cardiovascular Drugs
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/s5.pdf
October 01, 2007 - The
advent of Medicare Part D for outpatient prescription drugs has
drawn significant attention to the … or outcome misclassification), random er-
ror, confounding by clinical conditions, indications for drugs … , both alone and in comparison across
drugs. … Assessment of adherence
to and persistence on disease-modifying antirheumatic drugs
(DMARDs) in patients … Comparison of meta-
analytic results of indirect, direct, and combined comparisons of drugs
for chronic
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/TND_0264_01-14-2008.pdf
January 01, 2008 - Summary:
The nominator questions the comparative effectiveness of disease-modifying
antirheumatic drugs … idiopathic
arthritis
Intervention(s): Corticosteroids; Synthetic disease-modifying anti-rheumatic drugs … intramuscular gold); biologic DMARDs (i.e.,
etanercept, infliximab, adalimumab, anakinra)
Excluded drugs … penicillamine (toxicity), oral gold
(marginal efficacy), chloroquine and hydroxychloroquine (antimalarial drugs
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/migraine-prevention_executive.pdf
June 01, 2013 - ,
pediatricians prescribe drugs approved for adults or off-
label drugs (approved for clinical conditions … Off-Label Pharmacologic Agents: Antiepileptic Drugs
Topiramate. … Two small RCTs compared drugs with active
nonpharmacologic treatments. … No studies compared combined treatments for migraine
prevention with drugs alone. … Drugs for preventing migraine headaches
in children.
-
effectivehealthcare-admin.ahrq.gov/health-topics/medicare-prescription-drug-coverage
November 17, 2014 - It's insurance that helps people pay for prescription drugs. … You have to pay part of the cost of prescription drugs. … Toolkit
Research Report April 5, 2012
Data Points #9: Utilization of antidiabetic drugs
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/horizon-scan_research-2015.pdf
January 01, 2015 - When
considering categories of these interventions, such as drugs, devices, and procedures, new
pharmaceuticals … that new pharmaceuticals/biotechnologies and new off-label uses of existing
pharmaceuticals constitute … New Era of High-Cost Pharmaceuticals
The proportion of costs attributable to new specialty pharmaceuticals … Although anti-obesity drugs are not part of the high-cost paradigm seen with specialty
pharmaceuticals … The demand for new antiobesity drugs has been addressed in large part by three new oral
drugs approved
-
effectivehealthcare-admin.ahrq.gov/products/atrial-fibrillation/research
December 01, 2019 - Results
Our review included 182 articles (148 unique studies): 14 studies relevant to rate-control drugs … , 3 relevant to strict versus lenient rate control, 6 relevant to rate-control procedures versus drugs … in patients for whom initial pharmacotherapy was ineffective, 42 relevant to antiarrhythmic drugs and … electrical cardioversion for conversion to sinus rhythm, 83 relevant to rhythm-control procedures and drugs … review found high strength of evidence supporting pulmonary vein isolation (PVI) versus antiarrhythmic drugs
-
effectivehealthcare-admin.ahrq.gov/products/incident-user-design/research
August 01, 2019 - coronary heart disease events among patients using COX-2 selective non-steroidal anti-inflammatory drugs … For older drugs, a 365-day window may identify patients starting a new episode of therapy, but not … Most of these patients used other disease-modifying antirheumatic drugs (DMARDs) and have now switched … If newer drugs were started more recently, the newer drugs may appear safer than older drugs because … COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/dementia_hi_impact.pdf
January 01, 2012 - health care sector, horizon
scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices,
procedures … interventions expected to be within 0 to 4 years of potential diffusion (e.g., in phase III trials
for pharmaceuticals … Information is compiled for expert comment on topics at a granular level (i.e., similar
drugs in the … The search is on for ways to definitively diagnose AD and for drugs, biologics, and alternative or